Clinical immunology and multiplex biomarkers of human tuberculosis

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 4, 2015, Pages

  Walzl, Gerhard ^b   Haks, Mariëlle C ^a   Joosten, Simone A ^a   Kleynhans, Léanie ^b   Ronacher, Katharina ^b   Ottenhoff, Tom H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FRACTALKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 4; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 3; TOLL LIKE RECEPTOR 4;

ARTICLE; CELL FUNCTION; CLINICAL IMMUNOLOGY; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE PREDISPOSITION; GENETIC HETEROGENEITY; GENOMICS; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN MICROARRAY; PROTEOMICS; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TRANSCRIPTOMICS; TUBERCULOSIS; BLOOD; GENE EXPRESSION PROFILING; IMMUNOLOGY; IMMUNOPHENOTYPING; MYCOBACTERIUM TUBERCULOSIS;

BIOMARKERS; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; IMMUNOPHENOTYPING; MYCOBACTERIUM TUBERCULOSIS; PROTEOMICS; TUBERCULOSIS;

EID: 84926325956     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a018515     Document Type: Article

References (74)

1. Agranoff D, Fernandez-Reyes D, Papadopoulos MC, Rojas SA, Herbster M, Loosemore A, Tarelli E, Sheldon J, Schwenk A, Pollok R, et al. 2006. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 368: 1012-1021.
2. Al-Muhsen S, Casanova JL. 2008. The genetic heterogeneity of Mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immunol 122: 1043-1051; quiz 1052-1053.
3. Anderson ST, Kaforou M, Brent AJ, Wright VJ, Banwell CM, Chagaluka G, Crampin AC, Dockrell HM, French N, Hamilton MS, et al. 2014. Diagnosis of childhood TB in African countries by host RNA expression. N Engl J Med 370: 1712-1723.
4. Bacakoglu F, Basoglu OK, Cok G, Sayiner A, Ates M. 2001. Pulmonary tuberculosis in patients with diabetes mellitus. Respiration 68: 595-600.
5. Barry CE, 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. 2009. The spectrum of latent tuberculosis: Rethinking the biology and intervention strategies. Nat Rev Microbiol 7: 845- 855.
6. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, Wilkinson KA, Banchereau R, Skinner J, Wilkinson RJ, et al. 2010. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466: 973-977.
7. Bloom CI, Graham CM, Berry MP, Rozakeas F, Redford PS, Wang Y, Xu Z, Wilkinson KA, Wilkinson RJ, Kendrick Y, et al. 2013. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. 8: e70630.
8. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, et al. 2010. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363: 1005-1015.
9. Bustamante J, Arias AA, Vogt G, Picard C, Galicia LB, Prando C, Grant AV, Marchal CC, Hubeau M, Chapgier A, et al. 2011. Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nat Immunol 12: 213-221.
10. Chan MC, Chang KM, Chao WC, Lin LY, Kuo BI, Hsu JY, Wu CL. 2007. Evaluation of a new inflammatory molecule (triggering receptor expressed on myeloid cells-1) in the diagnosis of pleural effusion. Respirology 12: 333- 338.
11. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, Stichweh D, Blankenship D, Li L, Munagala I, et al. 2008. A modular analysis framework for blood genomics studies: Application to systemic lupus erythematosus. Immunity 29: 150-164.
12. Chegou NN, Black GF, Kidd M, van Helden PD, Walzl G. 2009. Host markers in QuantiFERON supernatants differentiate active TB from latent TB infection: Preliminary report. BMC Pulm Med 9: 21.
13. Chegou NN, Essone PN, Loxton AG, Stanley K, Black GF, van der Spuy GD, van Helden PD, Franken KL, Parida SK, Klein MR, et al. 2012. Potential of host markers produced by infection phase-dependent antigen-stimulated cells for the diagnosis of tuberculosis in a highly endemic area. PLoS ONE 7: e38501.
14. Chegou NN, Detjen AK, Thiart L, Walters E, Mandalakas AM, Hesseling AC, Walzl G. 2013. Utility of host markers detected in Quantiferon supernatants for the diagnosis of tuberculosis in children in a high-burden setting. PLoS ONE 8: e64226.
15. Cliff JM, Lee JS, Constantinou N, Cho JE, Clark TG, Ronacher K, King EC, Lukey PT, Duncan K, Van Helden PD, et al. 2013. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modula tion of the humoral immune response. J Infect Dis 207: 18-29.
16. Davies PD, Pai M. 2008. The diagnosis and misdiagnosis of tuberculosis. Int J Tuberc Lung Dis 12: 1226-1234.
17. De Groote MA, Nahid P, Jarlsberg L, Johnson JL, Weiner M, Muzanyi G, Janjic N, Sterling DG, Ochsner UA. 2013. Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment. PLoS ONE 8: e61002.
18. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. 2008. Predictive value of a whole blood IFNg assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 177: 1164-1170.
19. Dietrich J, Doherty TM. 2009. Interaction of Mycobacterium tuberculosis with the host: Consequences for vaccine development. APMIS 117: 440-457.
20. Djoba Siawaya JF, Beyers N, van Helden P, Walzl G. 2009a. Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis. Clin Exp Immunol 156: 69-77.
21. Djoba Siawaya JF, Chegou NN, van den Heuvel MM, Diacon AH, Beyers N, van Helden P, Walzl G. 2009b. Differential cytokine/chemokines and KL-6 profiles in patients with different forms of tuberculosis. Cytokine 47: 132-136.
22. du Plessis N, Loebenberg L, Kriel M, von Groote-Bidlingmaier F, Ribechini E, Loxton AG, van Helden PD, Lutz MB, Walzl G. 2013. Increased frequency of myeloidderived suppressor cells during active tuberculosis and after recent Mycobacterium tuberculosis infection suppresses T-cell function. Am J Respir Crit Care Med 188: 724-732.
23. Feruglio SL, Troseid M, Damas JK, Kvale D, Dyrhol-Riise AM. 2013. Soluble markers of the Toll-like receptor 4 pathway differentiate between active and latent tuberculosis and are associated with treatment responses. PLoS ONE 8: e69896.
24. Fletcher HA. 2007. Correlates of immune protection from tuberculosis. Curr Mol Med 7: 319-325.
25. Flynn JL, Chan J. 2003. Immune evasion by Mycobacterium tuberculosis: Living with the enemy. Curr Opin Immunol 15: 450-455.
26. Gorgun GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, Raje N, Munshi NC, Richardson PG, Anderson KC. 2013. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 121: 2975-2987.
27. Green AM, Mattila JT, Bigbee CL, Bongers KS, Lin PL, Flynn JL. 2010. CD4(þ) regulatory T cells in a cynomolgus macaque model of Mycobacterium tuberculosis infection. J Infect Dis 202: 533-541.
28. Harari A, Rozot V, Enders FB, Perreau M, Stalder JM, Nicod LP, Cavassini M, Calandra T, Blanchet CL, Jaton K, et al. 2011. Dominant TNF-aþ Mycobacterium tuberculosisspecific CD4þ T cell responses discriminate between latent infection and active disease. Nat Med 17: 372-376.
29. Higuchi K, Harada N, Fukazawa K, Mori T. 2008. Relationship between whole-blood interferon-g responses and the risk of active tuberculosis. Tuberculosis (Edinb) 88: 244-248.
30. Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, Nahid P, Steingart KR. 2010. Sputum monitoring during tuberculosis treatment for predicting outcome: Systematic review and meta-analysis. Lancet Infect Dis 10: 387- 394.
31. Jacobsen M, Repsilber D, Gutschmidt A, Neher A, Feldmann K, Mollenkopf HJ, Ziegler A, Kaufmann SH. 2007. Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med (Berl) 85: 613-621.
32. Janssens JP. 2007. Interferon-g release assay tests to rule out active tuberculosis. Eur Respir J 30: 183-184; author reply 184-185.
33. Jo EK, Park JK, Dockrell HM. 2003. Dynamics of cytokine generation in patients with active pulmonary tuberculosis. Curr Opin Infect Dis 16: 205-210.
34. Joosten SA, Ottenhoff TH. 2008. Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination. Hum Immunol 69: 760-770.
35. Joosten SA, Goeman JJ, Sutherland JS, Opmeer L, de Boer KG, Jacobsen M, Kaufmann SH, Finos L, Magis-Escurra C, Ota MO, et al. 2012. Identification of biomarkers for tuberculosis disease using a novel dual-color RT-MLPA assay. Genes Immun 13: 71-82.
36. Joosten SA, Fletcher HA, Ottenhoff TH. 2013. A helicopter perspective on TB biomarkers: Pathway and process based analysis of gene expression data provides new insight into TB pathogenesis. PLoS ONE 8: e73230.
37. Kaforou M, Wright VJ, Oni T, French N, Anderson ST, Bangani N, Banwell CM, Brent AJ, Crampin AC, Dockrell HM, et al. 2013. Detection of tuberculosis in HIV-infected and -uninfected African adults using whole blood RNA expression signatures: A case-control study. PLoS Med 10: e1001538.
38. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, Shen F, Eaton SM, Gaffen SL, Swain SL, et al. 2007. IL-23 and IL-17 in the establishment of protective pulmonary CD4þ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8: 369-377.
39. Koh GC, Schreiber MF, Bautista R, Maude RR, Dunachie S, Limmathurotsakul D, Day NP, Dougan G, Peacock SJ. 2013. Host responses to melioidosis and tuberculosis are both dominated by interferon-mediated signaling. PLoS ONE 8: e54961.
40. Kunnath-Velayudhan S, Salamon H, Wang HY, Davidow AL, Molina DM, Huynh VT, Cirillo DM, Michel G, Talbot EA, Perkins MD, et al. 2010. Dynamic antibody responses to the Mycobacterium tuberculosis proteome. Proc Natl Acad Sci 107: 14703-14708.
41. Lalvani A, Pathan AA, Durkan H, Wilkinson KA, Whelan A, Deeks JJ, Reece WH, Latif M, Pasvol G, Hill AV. 2001. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 357: 2017-2021.
42. Lee PP, Lau YL. 2013. Endemic infections in Southeast Asia provide new insights to the phenotypic spectrum of primary immunodeficiency disorders. Asian Pac J Allergy Immunol 31: 217-226.
43. Lee WI, Huang JL, Yeh KW, Jaing TH, Lin TY, Huang YC, Chiu CH. 2011. Immune defects in active mycobacterial diseases in patients with primary immunodeficiency diseases (PIDs). J Formos Med Assoc 110: 750-758.
44. Liu Q, Chen X, Hu C, Zhang R, Yue J, Wu G, Li X, Wu Y, Wen F. 2010. Serum protein profiling of smear-positive and smear-negative pulmonary tuberculosis using SELDITOF mass spectrometry. Lung 188: 15-23.
45. Maertzdorf J, Ota M, Repsilber D, Mollenkopf HJ, Weiner J, Hill PC, Kaufmann SH. 2011a. Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis. PLoS ONE 6: e26938.
46. Maertzdorf J, Repsilber D, Parida SK, Stanley K, Roberts T, Black G, Walzl G, Kaufmann SH. 2011b. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun 12: 15-22.
47. Maertzdorf J, Weiner J, 3rd, Mollenkopf HJ, Bauer T, Prasse A, Muller-Quernheim J, Kaufmann SH. 2012. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci 109: 7853-7858.
48. Maertzdorf J, Kaufmann SH., Weiner JIII. 2014. Toward a unified biosignature for tuberculosis. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a018531.
49. Mahapatra S, Hess AM, Johnson JL, Eisenach KD, Degroote MA, Gitta P, Joloba ML, Kaplan G, Walzl G, Boom WH, et al. 2014. A metabolic biosignature of early response to anti-tuberculosis treatment. BMC Infect Dis 14: 53.
50. Mihret A, Bekele Y, Bobosha K, Kidd M, Aseffa A, Howe R, Walzl G. 2013. Plasma cytokines and chemokines differentiate between active disease and non-active tuberculosis infection. J Infect 66: 357-365.
51. Miotto P, Mwangoka G, Valente IC, Norbis L, Sotgiu G, Bosu R, Ambrosi A, Codecasa LR, Goletti D, Matteelli A, et al. 2013. miRNA signatures in sera of patients with active pulmonary tuberculosis. PLoS ONE 8: e80149.
52. Mistry R, Cliff JM, Clayton CL, Beyers N, Mohamed YS, Wilson PA, Dockrell HM, Wallace DM, van Helden PD, Duncan K, et al. 2007. Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. J Infect Dis 195: 357-365.
53. Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, Shigeto E, Harada N, Mitarai S, Okada M, et al. 2004. Specific detection of tuberculosis infection: An interferon-g-based assay using new antigens. Am J Respir Crit Care Med 170: 59-64.
54. Ottenhoff TH. 2012a. The knowns and unknowns of the immunopathogenesis of tuberculosis. Int J Tuberc Lung Dis 16: 1424-1432.
55. Ottenhoff TH. 2012b. New pathways of protective and pathological host defense to mycobacteria. Trends Microbiol 20: 419-428.
56. Ottenhoff TH, Kaufmann SH. 2012. Vaccines against tuberculosis: Where are we and where do we need to go? PLoS Pathog 8: e1002607.
57. Ottenhoff TH, Verreck FA, Lichtenauer-Kaligis EG, Hoeve MA, Sanal O, van Dissel JT. 2002. Genetics, cytokines and human infectious disease: Lessons from weakly pathogenic mycobacteria and salmonellae. Nat Genet 32: 97-105.
58. Ottenhoff TH, Dass RH, Yang N, Zhang MM, Wong HE, Sahiratmadja E, Khor CC, Alisjahbana B, van Crevel R, Marzuki S, et al. 2012. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PLoS ONE 7: e45839.
59. Pollock KM, Whitworth HS, Montamat-Sicotte DJ, Grass L, Cooke GS, Kapembwa MS, Kon OM, Sampson RD, Taylor GP, Lalvani A. 2013. T-cell immunophenotyping distinguishes active from latent tuberculosis. J Infect Dis 208: 952-968.
60. Qin A, Cai W, Pan T, Wu K, Yang Q, Wang N, Liu Y, Yan D, Hu F, Guo P, et al. 2013. Expansion of monocytic myeloid-derived suppressor cells dampens T cell function in HIV-1-seropositive individuals. J Virol 87: 1477-1490.
61. Rahimov F, King OD, Leung DG, Bibat GM, Emerson CP Jr, Kunkel LM, Wagner KR. 2012. Transcriptional profiling in facioscapulohumeral muscular dystrophy to identify candidate biomarkers. Proc Natl Acad Sci 109: 16234- 16239.
62. Raja A. 2004. Immunology of tuberculosis. Indian J Med Res 120: 213-232.
63. Richeldi L, Mariani M, Losi M, Maselli F, Corbetta L, Buonsanti C, Colonna M, Sinigaglia F, Panina-Bordignon P, Fabbri LM. 2004. Triggering receptor expressed on myeloid cells: Role in the diagnosis of lung infections. Eur Respir J 24: 247-250.
64. Sahiratmadja E, Alisjahbana B, Buccheri S, Di Liberto D, de Boer T, Adnan I, van Crevel R, Klein MR, van Meijgaarden KE, Nelwan RH, et al. 2007. Plasma granulysin levels and cellular interferon-g production correlate with curative host responses in tuberculosis, while plasma interferon-g levels correlate with tuberculosis disease activity in adults. Tuberculosis (Edinb) 87: 312-321.
65. Sartain MJ, Slayden RA, Singh KK, Laal S, Belisle JT. 2006. Disease state differentiation and identification of tuberculosis biomarkers via native antigen array profiling. Mol Cell Proteomics 5: 2102-2113.
66. Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M, Dendukuri N. 2013. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev1: CD009593.
67. Sutherland JS, Hill PC, Adetifa IM, de Jong BC, Donkor S, Joosten SA, Opmeer L, Haks MC, Ottenhoff TH, Adegbola RA, et al. 2011. Identification of probable early-onset biomarkers for tuberculosis disease progression. PLoS ONE 6: e25230.
68. Sutherland JS, Loxton AG, Haks MC, Kassa D, Ambrose L, Lee JS, Ran L, van Baarle D, Maertzdorf J, Howe R, et al. 2013. Differential gene expression of activating Fcg receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity. Clin Microbiol Infect 20: O230-O238.
69. Tintinger GR, van der Merwe JJ, Fickl H, Rheeder P, Feldman C, Anderson R. 2012. Soluble triggering receptor expressed on myeloid cells in sputum of patients with community-acquired pneumonia or pulmonary tuberculosis: A pilot study. Eur J Clin Microbiol Infect Dis 31: 73-76.
70. Ulrichs T, Kosmiadi GA, Trusov V, Jorg S, Pradl L, Titukhina M, Mishenko V, Gushina N, Kaufmann SH. 2004. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J Pathol 204: 217-228.
71. van de Vosse E, Hoeve MA, Ottenhoff TH. 2004. Human genetics of intracellular infectious diseases: Molecular and cellular immunity against mycobacteria and salmonellae. Lancet Infect Dis 4: 739-749.
72. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. 2011. Immunological biomarkers of tuberculosis. Nat Rev Immunol 11: 343-354.
73. Wang LH, Yen CL, Chang TC, Liu CC, Shieh CC. 2012. Impact of molecular diagnosis on treating Mendelian susceptibility to mycobacterial diseases. J Microbiol Immunol Infect 45: 411-417.
74. Zhang X, Guo J, Fan S, Li Y, Wei L, Yang X, Jiang T, Chen Z, Wang C, Liu J, et al. 2013. Screening and identification of six serum microRNAs as novel potential combination biomarkers for pulmonary tuberculosis diagnosis. PLoS ONE 8: e81076.